Evidence map›Paper›PMID 30165978›Full record

ArticleJournal of the American College of Cardiology2018

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Jasper Tromp, B Daan Westenbrink, Wouter Ouwerkerk, Dirk J van Veldhuisen, Nilesh J Samani, Piotr Ponikowski, Marco Metra, Stefan D Anker, John G Cleland, Kenneth Dickstein and 9 more

Registry-linked trialOpen access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04857931 (A Biomarker Study Assessing the Effects of Colchicine on Inflammation and Extra-Cellular Matrix Turnover in Patients With Heart Failure and Preserved Ejection Fraction.), which is not on this map. Cited by 184 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 7 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04857931 phase2terminatednot on this mapstarted 2022, after this paper: background citation

A Biomarker Study Assessing the Effects of Colchicine on Inflammation and Extra-Cellular Matrix Turnover in Patients With Heart Failure and Preserved Ejection Fraction.

TypeinterventionalSponsorMontreal Heart InstituteRan2022 to 2023Enrolled14ConditionsHeart Failure, Inflammation, ColchicineArmsColchicine, Placebo
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 7 syntheses or guidelines pooled it, 298 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2020
    Trial
  17. Trial
  18. Review
  19. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  20. Observational

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 9 countries.

Jasper TrompDepartment of Cardiology, University of Groningen, Groningen, the Netherlands; National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore.
B Daan WestenbrinkDepartment of Cardiology, University of Groningen, Groningen, the Netherlands.
Wouter OuwerkerkDepartment of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands.
Dirk J van VeldhuisenDepartment of Cardiology, University of Groningen, Groningen, the Netherlands.
Nilesh J SamaniDepartment of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
Piotr PonikowskiDepartment of Heart Diseases, Wroclaw Medical University, and Cardiology Department, Military Hospital, Wroclaw, Poland.
Marco MetraInstitute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Stefan D AnkerDivision of Cardiology and Metabolism-Heart Failure, Cachexia & Sarcopenia, Department of Cardiology (CVK), and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité University Medicine, Berlin, Germany.
John G ClelandRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Kenneth DicksteinUniversity of Bergen, Stavanger University Hospital, Stavanger, Norway.
Gerasimos FilippatosNational and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece.
Pim van der HarstDepartment of Cardiology, University of Groningen, Groningen, the Netherlands.
Chim C LangDivision of Molecular & Clinical Medicine, University of Dundee, Dundee, United Kingdom.
Leong L NgDepartment of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
Faiez ZannadInserm CIC 1433, Université de Lorrain, CHU de Nancy, Nancy, France.
Aelko H ZwindermanDepartment of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands.
Hans L HillegeDepartment of Cardiology, University of Groningen, Groningen, the Netherlands.
Peter van der MeerDepartment of Cardiology, University of Groningen, Groningen, the Netherlands.
Adriaan A VoorsDepartment of Cardiology, University of Groningen, Groningen, the Netherlands. Electronic address: a.a.voors@umcg.nl.
University of Groningen · NLAmsterdam UMC Location University of Amsterdam · NLUniversity of Leicester · GBBerlin-Brandenburger Centrum für Regenerative Therapien · DEGlasgow Royal Infirmary · GBInserm · FRNational and Kapodistrian University of Athens · GRStavanger University Hospital · NOUniversity Medical Center Groningen · NLUniversity of Brescia · ITUniversity of Dundee · GBWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInformation on the pathophysiological differences between heart failure with reduced ejection fraction (HFrEF) versus heart failure with preserved ejection fraction (HFpEF) is needed

objectivesThe purpose of this study was to establish biological pathways specifically related to HFrEF and HFpEF.

methodsThe authors performed a network analysis to identify unique biomarker correlations in HFrEF and HFpEF using 92 biomarkers from different pathophysiological domains in a cohort of 1,544 heart failure (HF) patients. Data were independently validated in 804 patients with HF. Networks were enriched with existing knowledge on protein-protein interactions and translated into biological pathways uniquely related to HFrEF, HF with a midrange ejection fraction, and HFpEF.

resultsIn the index cohort (mean age 74 years; 34% female), 718 (47%) patients had HFrEF (left ventricular ejection fraction [LVEF] <40%) and 431 (27%) patients had HFpEF (LVEF ≥50%). A total of 8 (12%) correlations were unique for HFrEF and 6 (9%) were unique to HFpEF. Central proteins in HFrEF were N-terminal B-type natriuretic peptide, growth differentiation factor-15, interleukin-1 receptor type 1, and activating transcription factor 2, while central proteins in HFpEF were integrin subunit beta-2 and catenin beta-1. Biological pathways in HFrEF were related to DNA binding transcription factor activity, cellular protein metabolism, and regulation of nitric oxide biosynthesis. Unique pathways in patients with HFpEF were related to cytokine response, extracellular matrix organization, and inflammation. Biological pathways of patients with HF with a midrange ejection fraction were in between HFrEF and HFpEF.

conclusionsNetwork analysis showed that biomarker profiles specific for HFrEF are related to cellular proliferation and metabolism, whereas biomarker profiles specific for HFpEF are related to inflammation and extracellular matrix reorganization. (The BIOlogy Study to TAilored Treatment in Chronic Heart Failure [BIOSTAT-CHF]; EudraCT 2010-020808-29).

Indexed as

Activating Transcription Factor 2Agedbeta CateninBiomarkersCD18 AntigensFemaleGrowth Differentiation Factor 15Heart FailureHumansMaleNatriuretic Peptide, BrainReceptors, Interleukin-1 Type IStroke VolumeTranscriptional ActivationActivating Transcription Factor 2ATF2 protein, humanbeta CateninBiomarkersCD18 AntigensGrowth Differentiation Factor 15Natriuretic Peptide, BrainReceptors, Interleukin-1 Type IbiomarkersHFpEFHFrEFnetwork analysispathophysiology

Identifiers

PMID30165978
OpenAlexW2889352094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.